Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rony Dahan

Showing results (1-10 of 39) with videos related to

Pageof 4
Sort By:
Frontiers in Immunology|August 1, 2022
Next Generation CD40 Agonistic Antibodies for Cancer ImmunotherapyRan Salomon, Rony Dahan
Expert Reviews in Molecular Medicine|February 25, 2012
T-cell-receptor-like antibodies - generation, function and applicationsRony Dahan, Yoram Reiter
Cancer Cell|September 14, 2016
Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor EngagementRony Dahan, Jeffrey V Ravetch
Trends in Molecular Medicine|November 1, 2024
Fc-optimized checkpoint antibodies for cancer immunotherapyRony Dahan, Alan J Korman
Nature Medicine|February 5, 2020
Single-cell genomic approaches for developing the next generation of immunotherapiesIdo Yofe, Rony Dahan, Ido Amit
STAR Protocols|September 22, 2024
Protocol for assessing murine cell doublet engagement and subsequent effects using flow cytometry and imaging flow cytometryYuval Shapir Itai, Ziv Porat, Rony Dahan
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunityDavid A Knorr, Rony Dahan, Jeffrey V Ravetch
Annual Review of Immunology|April 28, 2017
Signaling by Antibodies: Recent ProgressStylianos Bournazos, Taia T Wang, Rony Dahan, et al.
Cancer Cell|August 31, 2017
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisRony Dahan, Emanuela Sega, John Engelhardt, et al.
Cancer Cell|September 17, 2015
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisRony Dahan, Emanuela Sega, John Engelhardt, et al.
Pageof 4

Showing results (1-10 of 39) with videos related to

Sort By:
Pageof 4
Frontiers in Immunology|August 1, 2022
Next Generation CD40 Agonistic Antibodies for Cancer ImmunotherapyRan Salomon, Rony Dahan
Expert Reviews in Molecular Medicine|February 25, 2012
T-cell-receptor-like antibodies - generation, function and applicationsRony Dahan, Yoram Reiter
Cancer Cell|September 14, 2016
Co-targeting of Adenosine Signaling Pathways for Immunotherapy: Potentiation by Fc Receptor EngagementRony Dahan, Jeffrey V Ravetch
Trends in Molecular Medicine|November 1, 2024
Fc-optimized checkpoint antibodies for cancer immunotherapyRony Dahan, Alan J Korman
Nature Medicine|February 5, 2020
Single-cell genomic approaches for developing the next generation of immunotherapiesIdo Yofe, Rony Dahan, Ido Amit
STAR Protocols|September 22, 2024
Protocol for assessing murine cell doublet engagement and subsequent effects using flow cytometry and imaging flow cytometryYuval Shapir Itai, Ziv Porat, Rony Dahan
Proceedings of the National Academy of Sciences of the United States of America|October 10, 2018
Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunityDavid A Knorr, Rony Dahan, Jeffrey V Ravetch
Annual Review of Immunology|April 28, 2017
Signaling by Antibodies: Recent ProgressStylianos Bournazos, Taia T Wang, Rony Dahan, et al.
Cancer Cell|August 31, 2017
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisRony Dahan, Emanuela Sega, John Engelhardt, et al.
Cancer Cell|September 17, 2015
FcγRs Modulate the Anti-tumor Activity of Antibodies Targeting the PD-1/PD-L1 AxisRony Dahan, Emanuela Sega, John Engelhardt, et al.
Pageof 4